Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Accelerates COVID-19 Vaccine Development, Targeting Phase III Start In September

Executive Summary

Phase I/IIa trial is poised to start in July versus a prior target of September, with a Phase III start targeted for late September. J&J also reported 2.1% pharma sales growth, reflecting an impact from COVID-19.

You may also be interested in...



Coronavirus Update: 'Positive News' Imminent From Oxford and AstraZeneca Vaccine

More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.

Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses

Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.

Pfizer Unveils Promising Early Data On COVID-19, Sends Moderna Shares Down

Pfizer and BioNTech appear to have the upper hand on mRNA rivals Moderna, but Phase III results will be the real test.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel